# A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

> **NCT02927314** · PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 60 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** CF102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02927314
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927314, "A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02927314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*